• 1
    Naclerio RM, Proud D, Togias A, Adkinson NFJ, Meyers DA, Kagey-Sobotka A et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985;313: 6570.
  • 2
    Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF Jr, Meyers DA, Norman PS et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128: 597602.
  • 3
    Baroody FM, Wagenmann M, Naclerio RM. Comparison of the secretory response of the nasal mucosa to methacholine and histamine. J Appl Physiol 1993;74: 26612671.
  • 4
    Wagenmann M, Baroody FM, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. The effect of terfenadine on unilateral nasal challenge with allergen. J Allergy Clin Immunol 1994;93: 594605.
  • 5
    Raphael GD, Meredith SD, Baraniuk JN, Druce HM, Banks SM, Kaliner MA. The pathophysiology of rhinitis: II. Assessment of the sources of protein in histamine-induced nasal secretions. Am Rev Respir Dis 1989;139: 791800.
  • 6
    Wagenmann M, Baroody FM, Cheng CC, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Bilateral increases in histamine after unilateral nasal allergen challenge. Am J Respir Crit Care Med 1997;155: 426431.
  • 7
    Proud D, Gwaltney JJ, Hendley JO, Dinarello CA, Gillis S, Schleimer RP. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J Infect Dis 1994;169: 10071013.
  • 8
    Röseler S, Holtappels G, Wagenmann M, Bachert C. Elevated levels of interleukins IL-1 beta, IL-6 and IL-8 in naturally acquired viral rhinitis. Eur Arch Otorhinolaryngol Suppl 1995;1: S61S63.
  • 9
    Bachert C, Wagenmann M, Rudack C, Hopken K, Hillebrandt M, Wang D et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998;53: 213.
  • 10
    Bachert C, Ganzer U. The role of pro-inflammatory cytokines in recruiting inflammatory cells in the nose. Laryngorhinootologie 1993;72: 585589.
  • 11
    Sim TC, Grant JA, Hilsmeier KA, Fukuda Y, Alam R. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am J Respir Crit Care Med 1994;149(2 Pt 1):339344.
  • 12
    Weido AJ, Reece LM, Alam R, Cook CK, Sim TC. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. Ann Allergy Asthma Immunol 1996;77: 407415.
  • 13
    Hauser U, Wagenmann M, Rudack C, Bachert C. Specific immunotherapy suppresses IL-1 beta and IL-8 levels in nasal secretions: a possible explanation for the inhibition of inflammatory cell migration. Otorhinolaryngol Nova 1997;1: 3139.
  • 14
    Mullarkey MF, Leiferman KM, Peters MS, Caro I, Roux ER, Hanna RK et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994;152: 20332041.
  • 15
    Rosenwasser LJ. Biologic activities of IL-1 and its role in human disease. J Allergy Clin Immunol 1998;102: 344350.
  • 16
    Bachert C, van Kempen M, Van Cauwenberge P. Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Int Arch Allergy Immunol 1999;118: 375379.
  • 17
    Nonaka M, Nonaka R, Jordana M, Dolovich J. GM-CSF, IL-8, IL-1R, TNF-alpha R, and HLA-DR in nasal epithelial cells in allergic rhinitis. Am J Respir Crit Care Med 1996;153: 16751681.
  • 18
    Moller A, Lippert U, Lessmann D, Kolde G, Hamann K, Welker P et al. Human mast cells produce IL-8. J Immunol 1993;151: 32613266.
  • 19
    Tachimoto H, Ebisawa M, Hasegawa T, Kashiwabara T, Ra C, Bochner BS et al. Reciprocal regulation of cultured human mast cell cytokine production by IL-4 and IFN-gamma. J Allergy Clin Immunol 2000;106(1 Pt 1):141149.
  • 20
    Gosset P, Tillie-Leblond I, Malaquin F, Durieu J, Wallaert B, Tonnel AB. Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages. Clin Exp Allergy 1997;27: 379388.
  • 21
    Borish L, Rosenwasser LJ. Cytokines in allergic inflammation. In: MiddletonE, ReedCE, EllisEF, AdkinsonNF, YungingerJW, BusseWW, editors. Allergy, principles and practice, 5th edn. St Louis, MO, USA: Mosby, 1998: 108123.
  • 22
    Finkelman FD, Morris SC. Development of an assay to measure in vivo cytokine production in the mouse. Int Immunol 1999;11: 18111818.
  • 23
    Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992;148: 23902394.
  • 24
    Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993;151: 38533865.
  • 25
    Linden M, Greiff L, Andersson M, Svensson C, Akerlund A, Bende M et al. Nasal cytokines in common cold and allergic rhinitis. Clin Exp Allergy 1995;25: 166172.
  • 26
    Frieri M, Therattil J, Chavarria V, Cosachov J, Kumar NS, Wang SF et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1998;81(5 Pt 1):431437.
  • 27
    Masuyama K, Jacobson MR, Rak S, Meng Q, Sudderick RM, Kay AB et al. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994;82: 192199.
  • 28
    Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107: 963970.
  • 29
    Denburg JA. Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Immunol Today 1999;20: 111113.
  • 30
    Rucci L, Masini E, Arbi RR, Giannella E, Fioretti C, Mannaioni PF et al. Vidian nerve resection, histamine turnover and mucosal mast cell function in patients with chronic hypertrophic non-allergic rhinitis. Agents Actions 1989;28: 224230.
  • 31
    Mosimann BL, White MV, Hohman RJ, Goldrich MS, Kaulbach HC, Kaliner MA. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J Allergy Clin Immunol 1993;92: 95104.
  • 32
    Church MK, el Lati S, Caulfield JP. Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 1991;94: 310318.
  • 33
    Okamoto Y, Shirotori K, Kudo K, Ishikawa K, Ito E, Togawa K et al. Cytokine expression after the topical administration of substance P to human nasal mucosa. The role of substance P in nasal allergy. J Immunol 1993;151: 43914398.
  • 34
    Sanico AM, Atsuta S, Proud D, Togias A. Dose-dependent effects of capsaicin nasal challenge: in vivo evidence of human airway neurogenic inflammation. J Allergy Clin Immunol 1997;100: 632641.